FIELD: pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry and is an antiarrhythmic agent, comprising (4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-2-[[2-[N-(7-methoxy-2-oxo-2H-chromen-4-yl)acetyl)amino]ethoxy]methyl]-1,4-dihydropyridine as an active substance.
EFFECT: invention allows to obtain a new compound with high antiarrhythmic activity and low toxicity.
1 cl, 4 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICOAGULANT AGENT OF INDIRECT ACTION ON BASIS OF DIUMANCAL | 2018 |
|
RU2671983C9 |
| MEDICAMENT WITH PROLONGED ANTI-CALCIUM ACTIVITY IN THE FORM OF 1/10% INTRAVENOUS SOLUTION | 2004 |
|
RU2255728C1 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| ANTIARRHYTHMIC MEDICATION BASED ON 4-METHYL-7,7'-ETHYLENEDIOXY-2H-1-DIBENZOPYRAN-2,2'-DIONE | 2010 |
|
RU2427368C1 |
| IMMUNOMODULATORY AND ANTIVIRAL AGENT BASED ON (2-((COUMARIN-7-YL)OXY)ETHYL) 3-HYDROXY-20(29)-LUPEN-28-OATE | 2018 |
|
RU2686743C1 |
| HYBRID COUMARINS WITH INDIRECT ANTICOAGULANT ACTION | 2018 |
|
RU2672062C1 |
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| AGENT FOR TREATMENT OF PATIENT WITH HEART ISCHEMIC DISEASE | 1998 |
|
RU2155036C2 |
| FLUORATED 4-FURFURYL-3,4-DIHYDRO-2H-BENZO[1,4]THIAZINE-1,1-DIOXIDES WITH HIGH ARRYTHMIC ACTIVITY | 2016 |
|
RU2626239C1 |
| 5-AMINO-EXO-3-AZATRICYCLO[5.2.1.0]-DECAN-4-ONE HAVING ANTI-ARRHYTHMIC, ANTI-INFLAMMATION, ANALGESIC, AND NOOTHROPIC ACTIVITY | 2005 |
|
RU2281938C1 |
